These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 25863599)

  • 1. Assessment of anti-factor Xa activity of heparin in binary parenteral nutrition admixtures for premature neonates.
    Foinard A; Perez M; Barthélémy C; Lannoy D; Flamein F; Storme L; Tournoys A; Décaudin B; Odou P
    Ann Pharm Fr; 2015 Jul; 73(4):277-80. PubMed ID: 25863599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid peroxidation assessment by malondialdehyde measurement in parenteral nutrition solutions for newborn infants: a pilot study.
    Picaud JC; Steghens JP; Auxenfans C; Barbieux A; Laborie S; Claris O
    Acta Paediatr; 2004 Feb; 93(2):241-5. PubMed ID: 15046281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Assessment of Interaction Between Amino Acids and Copper in Neonatal Parenteral Nutrition.
    Foinard A; Perez M; Barthélémy C; Lannoy D; Flamein F; Storme L; Addad A; Bout MA; Décaudin B; Odou P
    JPEN J Parenter Enteral Nutr; 2016 Aug; 40(6):827-34. PubMed ID: 25712958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The establishment and validation of efficient assays for anti-IIa and anti-Xa activities of heparin sodium and heparin calcium.
    Suzuki T; Ishii-Watabe A; Hashii N; Nakagawa Y; Takahashi T; Ebisawa A; Nishi S; Fujita N; Bando A; Sekimoto Y; Miyata K; Endo T; Otsu T; Sugimoto S; Kondou T; Fujita Y; Miyanaga N; Mashimo M; Shimada N; Yoden H; Shimamura H; Kurata Y; Koyama S; Kawasaki N
    Biologicals; 2013 Nov; 41(6):415-23. PubMed ID: 24095600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity.
    Manlhiot C; Gruenwald CE; Holtby HM; Brandão LR; Chan AK; Van Arsdell GS; McCrindle BW
    J Thorac Cardiovasc Surg; 2016 Feb; 151(2):444-50. PubMed ID: 26553458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of heparin anticoagulant activity over time in parenteral nutrition solutions.
    Hensrud DD; Burritt MF; Hall LG
    JPEN J Parenter Enteral Nutr; 1996; 20(3):219-21. PubMed ID: 8776697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of anti-factor Xa activity for heparin and related products by chromogenic assays and thrombin generation tests].
    Suzuki A; Kaneko M; Kanno N; Yatomi Y
    Rinsho Byori; 2013 Jul; 61(7):567-75. PubMed ID: 24205696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Physicochemical stability of individualized parenteral nutrition in neonatal period].
    Lombardi J; Semama DS
    Ann Pharm Fr; 2018 Mar; 76(2):154-162. PubMed ID: 29395015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-xa directed protocol for anticoagulation management in children supported with extracorporeal membrane oxygenation.
    O'Meara LC; Alten JA; Goldberg KG; Timpa JG; Phillips J; Laney D; Borasino S
    ASAIO J; 2015; 61(3):339-44. PubMed ID: 25710768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative performance of three anti-factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin.
    Lehman CM; Rettmann JA; Wilson LW; Markewitz BA
    Am J Clin Pathol; 2006 Sep; 126(3):416-21. PubMed ID: 16880140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Advantages and special features of hospital preparations of parenteral nutrition in neonatalogy].
    Baudouin A; Diouf E; Tall ML; Duval S; Provôt S; Picaud JC; Claris O; Pivot C; Pirot F
    Ann Pharm Fr; 2015 Mar; 73(2):150-9. PubMed ID: 25745946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.
    Königsbrügge O; Quehenberger P; Belik S; Weigel G; Seger C; Griesmacher A; Pabinger I; Ay C
    Ann Hematol; 2015 Sep; 94(9):1463-71. PubMed ID: 26025632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.
    Hicks JK; Shelton CM; Sahni JK; Christensen ML
    Ann Pharmacother; 2012; 46(7-8):943-51. PubMed ID: 22828970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of nadroparin, enoxaparin, and unfractionated heparin on endogenous formation of factor Xa and IIa and on thrombelastometry profiles in cord versus adult blood.
    Cvirn G; Hoerl G; Tafeit E; Heinl N; Wodrig K; Wagner T; Koestenberger M; Juergens G
    Neonatology; 2011; 100(1):23-31. PubMed ID: 21150227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*.
    Liveris A; Bello RA; Friedmann P; Duffy MA; Manwani D; Killinger JS; Rodriquez D; Weinstein S
    Pediatr Crit Care Med; 2014 Feb; 15(2):e72-9. PubMed ID: 24335992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.